Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the ...

Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast growth factor 21 analog, designed to treat patients with biopsy-confirmed ...

Akero Therapeutics (AKRO) reported 96-week data in its trial of advanced MASH patients, and there seem really significant ...

It was the best of biotech times, it was the worst of biotech times: One company soars, another stumbles and a third outlines ...

Home > Pressemitteilung: Two million euros for better therapy ... MHH molecular biologist investigates the body's own repair programme in the heart muscle and receives the renowned ERC Advanced Grant ...

Madrigal Pharmaceuticals (MDGL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yasmeen ...

Akero Therapeutics nearly doubled Monday — and pulled 89bio shares higher — after the company's treatment for MASH ...

Canaccord Genuity adjusted its outlook on Akero Therapeutics (NASDAQ: NASDAQ:AKRO) shares, raising the price target to $73 ...

J.P. Morgan, Morgan Stanley and Jefferies are acting as joint book-running managers for the proposed offering.

When cystic fibrosis hits your lungs hard, hit back. Everything you need to know about getting your lungs back into shape is ...

A dietary supplement used to build muscle – or prevent muscle loss as a result of ageing or illness – is to be trialled as a potential treatment for chronic liver disease.

What a difference 60 weeks can make. That’s the lesson Akero Therapeutics Inc. shared with the rollout of what executives called “unprecedented” data from the phase IIb Symmetry trial testing ...